Intra-articular Corticosteroid Injections for Knee Osteoarthritis
Intra-articular corticosteroid injections are the first-line injectable treatment for knee osteoarthritis when conservative measures fail, supported by 19 high-quality and 6 moderate-quality studies, though benefits typically last only 3 months. 1
Recommended Injectable Options (in order of evidence strength)
First-Line: Corticosteroid Injections
- Corticosteroids have the strongest evidence base among all intra-articular options for knee OA 1
- Particularly indicated for acute pain exacerbations, especially when accompanied by joint effusion 1
- Provide significant pain relief and functional improvement lasting weeks to months 2, 3
- Triamcinolone hexacetonide is superior to triamcinolone acetonide and should be the preferred corticosteroid formulation 2
Dosing and Administration for Corticosteroids
- Knee joint dosing: 20-80 mg for large joints (methylprednisolone acetate) 4
- Alternative: 5-15 mg for knee joints (triamcinolone acetonide), with doses up to 40 mg for larger areas 5
- Inject directly into the synovial space using strict aseptic technique 4, 5
- Use 20-24 gauge needle; aspirate synovial fluid first if excessive effusion present 4
- Frequency: Repeat injections at intervals of 1-5 weeks depending on degree of relief obtained 4
- Single injections into multiple joints up to total of 80 mg have been given 5
Second-Line: Platelet-Rich Plasma (PRP)
- Consider PRP only after corticosteroid failure or in patients with mild-to-moderate OA 1
- Supported by 2 high-quality and 1 moderate-quality study showing reduced pain and improved function 1
- Critical caveat: PRP shows worse treatment response in severe knee OA (Kellgren-Lawrence grade 3-4) 1
- Concerns exist regarding cost and safety profile 1
- Network meta-analysis shows PRP has highest P-Score for WOMAC improvement at 6 months 6
NOT Recommended: Hyaluronic Acid
- The AAOS recommends AGAINST routine use of hyaluronic acid in knee OA 1
- Despite 17 high-quality and 11 moderate-quality studies, evidence is inconsistent 1
- Number needed to treat is 17 patients, but cannot identify which subset benefits 1
- The ACR provides no recommendation (evidence too equivocal) 1
- A 2023 high-quality RCT found no superior effect compared to placebo in patients with low baseline pain 7
Contraindications and Precautions
Absolute Contraindications
- Active joint infection or septic arthritis 4, 5
- Bacteremia or skin infection overlying injection site 4
- Known hypersensitivity to corticosteroid preparations 4, 5
Relative Contraindications and Warnings
- Diabetes mellitus: Risk of systemic hyperglycemia after corticosteroid injection 3
- Avoid injecting into tendon substance (causes tendon rupture); inject into tendon sheath only 4, 5
- Repeated corticosteroid injections may cause joint degradation and cartilage damage 3
- Anatomically inaccessible joints (spinal, sacroiliac) are unsuitable 4
- Use caution with hip joint injections due to proximity to large blood vessels 4
Post-Injection Monitoring
- Cover injection site with sterile dressing 4
- Move joint gently after injection to mix suspension with synovial fluid 4
- Monitor for signs of infection (septic arthritis is a known complication) 3
- Watch for local pain and swelling lasting a few days (common minor side effect) 8
Clinical Decision Algorithm
For patients failing oral NSAIDs, acetaminophen, physical therapy, and weight control:
If acute pain flare with effusion present: Intra-articular corticosteroid injection (20-80 mg methylprednisolone or 5-15 mg triamcinolone hexacetonide) 1, 2
If chronic pain without severe radiographic changes (KL grade 1-2): Consider corticosteroid first; if inadequate response after 3 months, consider PRP 1, 6
If severe OA (KL grade 3-4): Corticosteroid injection only; avoid PRP due to poor response in severe disease 1
Avoid hyaluronic acid as routine treatment given inconsistent evidence and AAOS recommendation against it 1
Common Pitfalls to Avoid
- Failure to enter joint space is the most common cause of treatment failure 4
- Injecting into surrounding tissue rather than synovial cavity leads to tissue atrophy and no benefit 4
- Mixing corticosteroid suspension with other solutions causes physical incompatibilities 4
- Allowing suspension to settle in syringe before injection reduces efficacy 5
- Using inadequate needle length (minimum 1.5 inches for adults, longer for obese patients) 5
- Expecting benefits beyond 3 months from corticosteroid injections 1